By Donna Loyle, communications specialist, LIMR
Main Line Health is participating in a clinical trial that is studying the safety and effectiveness of the ACURATE neo2™ aortic valve system for transcatheter aortic valve replacement in symptomatic patients diagnosed with aortic stenosis. Eligible patients are those at intermediate or greater risk for standard surgical aortic valve replacement.
Study participants undergo implantation with either the ACURATE neo2™ or another commercially available device. Patients will be assessed at baseline, peri- and post-procedure, at discharge, 30 days, six months, one year, and then annually for up to five years.
The Main Line Health principal investigator for the ACURATE IDE trial is Eric Gnall, DO. For more, visit https://www.mainlinehealth.org/research/clinical-trials/acurate-ide